Ben George, MD

William F. Stapp Endowed Chair; Professor of Medicine; Director, Phase 1 Clinical Trials Program; Associate Director for Cancer Genomics and Precision Medicine; Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Malayalam

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Dr. George graduated from Medical College Thiruvananthapuram, in Kerala, India in 1998. He was a PhD candidate in Pathology at the Keck School of Medicine (University of Southern California) in Los Angeles, CA from 1999-2004. In 2005, Dr. George completed an internship in Internal Medicine at the Medical College of Ohio and subsequently his residency at Gunderson Lutheran Medical Center in La Crosse, WI. He then completed a fellowship in Hematology and Oncology at the Medical College of Wisconsin (2007-2010). Most recently, Dr. George completed a dedicated fellowship in Gastrointestinal Medical Oncology at the MD Anderson Cancer Center in Houston, Texas. He is board certified in medical oncology and hematology.

Research Interests

Dr. Ben George joined the Medical College of Wisconsin faculty in 2011 as an associate professor of medicine in the division of hematology and oncology. Dr. George specializes in gastrointestinal medical oncology. His interests include colorectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, small bowel and appendiceal neoplasms, cholangiocarcinoma, and hepatocellular carcinoma. His current research interests are focused on colorectal cancer and pancreatic cancer.

Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.

(Shitara K, Falcone A, Fakih MG, George B, Sundar R, Ranjan S, Van Cutsem E.) Oncologist. 2024 Feb 16 PMID: 38366864 02/17/2024
Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.

(George B, Kudryashova O, Kravets A, Thalji S, Malarkannan S, Kurzrock R, Chernyavskaya E, Gusakova M, Kravchenko D, Tychinin D, Savin E, Alekseeva L, Butusova A, Bagaev A, Shin N, Brown JH, Sethi I, Wang D, Taylor B, McFall T, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S.) Gastroenterology. 2024 Jan 25 PMID: 38280684 SCOPUS ID: 2-s2.0-85188891214 01/28/2024
Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.

(de Ortiz de Choudens S, Visotcky A, Banerjee A, Aldakkak M, Tsai S, Evans DB, Christians KK, Clarke CN, George B, Shreenivas A, Kamgar M, Chakrabarti S, Dua KS, Khan AH, Madhavan S, Erickson BA, Hall WA.) Cancer Med. 2023 Dec 22;13(1) PMID: 38140796 PMCID: PMC10807686 SCOPUS ID: 2-s2.0-85180644976 12/23/2023
Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer.

(Thalji SZ, Fernando D, Dua KS, Madhavan S, Chisholm P, Smith ZL, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Evans DB, Tsai S.) Ann Surg. 2023 Dec 01;278(6):e1224-e1231 PMID: 37078282 SCOPUS ID: 2-s2.0-85176508848 04/20/2023
ALK fusions in the pan-cancer setting: another tumor-agnostic target?

(Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R.) NPJ Precis Oncol. 2023 Sep 29;7(1):101 PMID: 37773318 PMCID: PMC10542332 SCOPUS ID: 2-s2.0-85173930134 09/29/2023
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).

(Shitara K, George B, Taieb J, Sundar R, Fakih MG, Makris L, Benhadji KA, Ghidini M.) J Cancer Res Clin Oncol. 2023 Sep;149(11):9361-9374 PMID: 37213030 PMCID: PMC10374776 05/22/2023
Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity.

(Thalji SZ, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Chisholm P, Kulkarni N, Doucette S, Evans DB, Tsai S.) J Surg Oncol. 2023 Jul;128(1):41-50 PMID: 36960919 SCOPUS ID: 2-s2.0-85152449940 03/25/2023
A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence.

(Moroney J, Trivella J, George B, White SB.) Cancers (Basel). 2023 May 17;15(10) PMID: 37345129 PMCID: PMC10216313 SCOPUS ID: 2-s2.0-85160713805 06/22/2023
ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer.

(Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S.) Ann Surg Oncol. 2023 May;30(5):3022 PMID: 36877324 SCOPUS ID: 2-s2.0-85152164746 03/07/2023
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.

(Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S.) Ann Surg Oncol. 2023 May;30(5):3013-3021 PMID: 36788189 SCOPUS ID: 2-s2.0-85147934173 02/15/2023
Definitive Chemoradiation Associated with Improved Survival Outcomes in Patients with Synchronous Oligometastatic Esophageal Cancer.

(Matoska T, Banerjee A, Shreenivas A, Jurkowski L, Shukla ME, Gore EM, Linsky P, Gasparri M, George B, Johnstone C, Johnstone D, Puckett LL.) Cancers (Basel). 2023 Apr 28;15(9) PMID: 37173988 PMCID: PMC10177457 SCOPUS ID: 2-s2.0-85159164697 05/13/2023
Comprehensive genomic profiling: Does timing matter?

(Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B.) Front Oncol. 2023;13:1025367 PMID: 36865796 PMCID: PMC9971445 03/04/2023